Lightcalls.com
 

A surprising fresh study offers pr...

A surprising fresh study offers proof that heart attacks are caused by means of internal inflammation.

The November 14 2002 issue of the strange England Journal of Medicine reports that inflammation is the most numerous powerful trigger of heart attacks, worse than cholesterol

The article was based in succession a study that followed 28000 women for eight years. to the full 77 percent of those who put up withed heart attacks or strokes had cholesterol of the same heights within the normal range--and 45 percent had flushs in the ideal range.

"That means we're missing large numbers of individuals at risk," says Paul Ridker, MD of Brigham and Women's Hospital in Boston.

The opportunity to which he give in charges is a blood test that measures something called C-reactive protein, or CRP a measure of inflammation. The cogitation found that the CRP touchstone did a better job predicting heart-disease risk than cholesterol testing. Compared to patients with high cholesterol those with high horizontals of inflammation were twice as likely to die from heart attacks and strokes

Taken together, the CRP and cholesterol trials did the best job in predicting coronary problems



"In other words, individuals who have the two abnormalities are at very high risk. Individuals without either have relatively subdued risk," Ridker said.

ofttimes the fatty buildups that line arteries become inflamed as white relations cells invade them in a misguided defense attempt. Other possible inflammation triggers include high descendants pressure, smoking and lingering low-level infections similar as chronic gum disease.

Inflammation is contemplation to weaken fatty buildups, or plaques, making them more likely to split open A piece of plaque can then form a concretion that can cause a heart attack.

The righteous news is that inflammation treatments are available. Cholesterol-lowering mix with drugss called statins can reduce the inflammation, as can a daily dose of aspirin.

through the whole extent of the past five years, Ridker has built a hardy case for the "inflammation hypothesis." With this latest cogitation many believe the evidence is now overwhelming that inflammation is a central, equable major, factor in cardiovascular disease.

COPYRIGHT 2003 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2003 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.